Bayer has announced that BlueRock Therapeutics has established a new site for cell therapy innovation on Bayer’s campus in Berlin & intends to initiate a global non-interventional study for #Parkinsons patients in the second half of 2022
bluerocktx.com/bayers-bluer...
About the BRT-DA01 Phase I Trial
The primary objective of the PhI trial is to assess the safety and tolerability of BRT-DA01 transplantation at one-year post-transplant. The secondary objectives of the trial are to assess the evidence of transplanted cell survival and motor effects at one- and two-years post-transplant, to evaluate continued safety and tolerability at two years, and to assess feasibility of transplantation.
In the United States, the trial was initiated at Weill Cornell Medicine with Dr. Harini Sarva, M.D. as the Principal Investigator (PI) and first surgeries being performed by Dr. Viviane Tabar, Chair of the Department of Neurosurgery at Memorial Sloan Kettering Cancer Center. Additional Neurology sites were added at the University of California, Irvine, under the guidance of Dr. Claire Henchcliffe, M.D., D.Phil., F.A.A.N., F.A.N.A. (PI), and at the University Health Network (UHN), under the guidance of Dr. Lozano, O.C., M.D., Ph.D., F.R.C.S.C., F.R.S.C., F.C.A.H.S. (PI) and Dr. Alfonso Fasano, M.D., PhD., Chair in Neuromodulation and Multi-Disciplinary Care, UHN and UoT.
More information about the Phase I trial is available at clinicaltrials.gov (NCT#04802733).
As a next step, BlueRock Therapeutics plans to initiate a global non-interventional study in the second half of 2022.
More information about the non-interventional study is available at clinicaltrials.gov (NCT#05363046).
Vibrating Gloves for Parkinson's Disease
Phase 3 Positive Topline Results for Tavapadon 
Phase 3, the Lighthouse study, Biogen and Denali, LRRK2 inhibitor BIIB122; New clinical trial registered
